Figure 2 | British Journal of Cancer

Figure 2

From: Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

Figure 2

Bone turnover marker evolution during follow-up in BC patients. (A) Beta-isomer of carboxy-terminal telopeptide of collagen I (β-CTX); (B) bone alkaline phosphatase (BALP); (C) procollagen type I amino-terminal propeptide (PINP). Values (y-axis) are shown as median and standard deviation (BALP and PINP in μg l−1, and β-CTX in ng ml−1). At x-axis, time of follow-up (months) and number of patients alive (n) are shown. **Statistically significant differences with respect to baseline levels (P<0.05).

Back to article page